European Urology Oncology Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer Umberto Capitanio, Alessandro Larcher, Francesco Cianflone, Francesco Trevisani, Alessandro Nini, Alexandre Mottrie, Andrea Mari, Riccardo Campi, Riccardo Tellini, Alberto Briganti, Alessandro Veccia, Hendrik Van Poppel, Marco Carini, Claudio Simeone, Andrea Salonia, Andrea Minervini, Alessandro Antonelli, Francesco Montorsi, Roberto Bertini European Urology Oncology DOI: 10.1016/j.euo.2019.02.006 Copyright © 2019 European Association of Urology Terms and Conditions
Fig. 1 Smoothed Poisson cumulative curves depicting hypertension (HT) and major cardiovascular event (MCE) rates in 572 patients diagnosed with a single clinical T1–2 renal mass who underwent NSS between 1987 and 2016. The 5-yr HT and MCE rates are 3.3% and 6.3%, respectively. NSS=nephron-sparing surgery. European Urology Oncology DOI: (10.1016/j.euo.2019.02.006) Copyright © 2019 European Association of Urology Terms and Conditions
Fig. 2 Smoothed Poisson cumulative curves depicting hypertension (HT) and major cardiovascular event (MCE) rates in 326 patients diagnosed with a single clinical T1–2 renal mass who underwent RN between 1987 and 2016. The 5-yr HT and MCE rates are 5.1% and 4.2%, respectively. RN=radical nephrectomy. European Urology Oncology DOI: (10.1016/j.euo.2019.02.006) Copyright © 2019 European Association of Urology Terms and Conditions